Michèle Cavo

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial”.

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30525-8

N/A

5.3DataRank · unranked

407 citations

Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto +15 more

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Leukemia(2020)10.1038/s41375-020-0718-z

N/A

2.9DataRank · unranked

98 citations

Ajai Chari, Yaël C. Cohen, Andrew Spencer, Peter M. Voorhees, Jane Estell +16 more

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Journal of Clinical Oncology(2025)10.1200/jco-24-01893

N/A

2.3DataRank · unranked

151 citations

Faith E. Davies, Mehmet Samur, Jill Corre, Mattia D’Agostino, Martin Kaiser +41 more

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

Blood Advances(2020)10.1182/bloodadvances.2019000779

N/A

0.661DataRank · unranked

81 citations

Giulia Biancon, Filippo Bagnoli, Chiara De Philippis, Francesco Maura, Even H Rustad +15 more

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

The Lancet Haematology(2025)10.1016/s2352-3026(25)00139-5

N/A

0.241DataRank · unranked

4 citations

Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto +13 more